{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:47:15Z","timestamp":1762004835397},"reference-count":28,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for Promotion of Science","doi-asserted-by":"crossref","award":["15K0960"],"award-info":[{"award-number":["15K0960"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ymgme.2016.10.003","type":"journal-article","created":{"date-parts":[[2016,10,15]],"date-time":"2016-10-15T22:24:53Z","timestamp":1476570293000},"page":"116-120","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy"],"prefix":"10.1016","volume":"120","author":[{"given":"Takashi","family":"Kodama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayasu","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2016.10.003_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2016.10.003_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International collaborative Fabry disease study group. Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of \u03b1-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0030","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","article-title":"Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis","volume":"3","author":"Beck","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0045","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0055","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2016.10.003_bb0060","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry","volume":"85","author":"Lavoie","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0065","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0070","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/092986713804806685","article-title":"A metabolomic study reveals novel plasma lyso-Gb3 analogues as Fabry disease biomarkers","volume":"20","author":"Dupont","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0075","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0080","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb3-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cca.2014.08.002","article-title":"Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry","volume":"438","author":"Auray-Blais","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2016.10.003_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127048","article-title":"Nano-LC-MS\/MS for quantification of lyso-Gb3 and its analogues reveals a useful biomarker for Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2016.10.003_bb0095","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1194\/jlr.M017178","article-title":"Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice","volume":"52","author":"Durant","year":"2011","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0100","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00216-014-8402-7","article-title":"Fabry disease: renal sphingolipid distribution in the \u03b1-Gal A knockout mouse model by mass spectrometric and immunohistochemical imaging","volume":"407","author":"Kuchar","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144958","article-title":"Distributions of globotriaosylceramide isoforms, and globotriaosylsphingosine and its analogues in an \u03b1-galactosidase A knockout mouse, a model of Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2016.10.003_bb0110","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0115","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease","volume":"5","author":"Marshall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2016.10.003_bb0125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2119\/molmed.2011.00248","article-title":"Efficient uptake of recombinant \u03b1-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys","volume":"18","author":"Tsukimura","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of \u03b1-galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0135","doi-asserted-by":"crossref","first-page":"13112","DOI":"10.1016\/S0021-9258(18)43014-1","article-title":"Testosterone effects on the induction and urinary excretion of mouse kidney glycosphingolipids associated with lysosomes","volume":"256","author":"McCluer","year":"1981","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2016.10.003_bb0140","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2010.08.006","article-title":"Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease","volume":"399","author":"Togawa","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216301548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216301548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T13:05:08Z","timestamp":1657458308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216301548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":28,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1096719216301548"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.10.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}